type DX does this by evaluating specific genes in colon tumors to determine the likelihood that cancer cells will spread and thus cause a recurrence of colon cancer after surgical resection. Information provided by Onco
type DX has been shown that the independent significance beyond the currently used measures to determine the risk of colon cancer recurrence. For people recently diagnosed with colon cancer stage II, Onco
DX-type test may be an appropriate part of treatment planning. For more information on Onco
type DX colon cancer analysis, please call: (866) ONCOTYPE or visit
type DX colon cancer publications and presentations, in contrast to breast cancer, there are several established biomarkers stage II colon cancer risk assessment and decision-making about treatment. Deficiencies in DNA mismatch repair (MMR) gene function, either due to decreased expression of the gene or mutation, leads to accumulation of DNA alterations, which may manifest as an abnormal contraction or elongation of microsatellite DNA sequences, also known as microsatellite instability (MSI). In patients with inadequate MMR (MMR-D), colon tumors has been shown that significantly lower the risk of colon cancer recurrence, and thus MMR testing may be an addition to the information provided by Onco
type DX colon cancer analysis . Genomic Health is working to facilitate the inclusion of MMR testing in treatment planning to stage colon cancer II. For stage II and III colon cancer, the most commonly used adjuvant therapy include a combination of fluoropyrimidine and oxaliplatin.
No comments:
Post a Comment